Answers are grounded in this paper and cite their sources.
Purpose To determine the prevalence of sarcopenia and sarcopenic obesity (SO) in patients with type-2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD). Methods This cross-sectional study included 60 T2DM patients (30 with CVD and 30 without, aged 40-70 years, 80% males). Data collection included body composition analysis using bio-impedance, hand grip strength measurement and gait-speed assessment. Sarcopenia was defined using the Asian Working Group for Sarcopenia (AWGS-19) guidelines, while SO was defined using a body-mass index, waist circumference and percentage of body fat. SPSS software version 23.0 was used. P < .05 was significant. Results Overall sarcopenia (including possible sarcopenia or sarcopenia) was found to be significantly higher in patients with CVD as compared to those without CVD (70% vs. 40%; P = .020). Although numerically greater (in patients with CVD), no statistically significant difference was found in the prevalence of SO (30% vs. 16.7%; P = .222). Conclusion Our study found that the prevalence of overall sarcopenia was significantly higher in patients with T2DM and CVD compared to those without CVD. Sarcopenia appears to be a potential independent risk factor in predicting risk of CVD in patients with T2DM.
No takes yet. Share an insight, caveat, or question.
Wasir et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: